International Journal of
Reproductive Biomedicine
Mon, Oct 7, 2024
[Archive]
Volume 21, Issue 4 (April 2023)
IJRM 2023, 21(4): 295-302 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Forghani F, Ranjbar N, Jahantigh D. The presence, severity, and onset of preeclampsia is associated with maternal interleukin-23 level: A case-control study. IJRM 2023; 21 (4) :295-302
URL: http://ijrm.ir/article-1-2604-en.html
URL: http://ijrm.ir/article-1-2604-en.html
1- Department of Obstetrics and Gynecology, Zabol University of Medical Sciences, Zabol, Iran. Department of Obstetrics and Gynecology, Zahedan University of Medical Sciences, Zahedan, Iran.
2- Department of Clinical Biochemistry, Zahedan University of Medical Sciences, Zahedan, Iran.
3- Department of Biology, Faculty of Science, University of Sistan and Baluchestan, Zahedan, Iran. ,danial_jahantigh@yahoo.com
2- Department of Clinical Biochemistry, Zahedan University of Medical Sciences, Zahedan, Iran.
3- Department of Biology, Faculty of Science, University of Sistan and Baluchestan, Zahedan, Iran. ,
Abstract: (773 Views)
Background: Scientific evidence support that imbalance between inflammatory and anti-inflammatory cytokines play a critical role in preeclampsia (PE).
Objective: To investigate the relationship between the maternal serum level of interleukin (IL)-23, a pro-inflammatory cytokine, PE and its severity risk was investigated.
Materials and Methods: The case-control study included a total of 145 women counting 75 PE cases, 35 healthy pregnant and 35 healthy non-pregnant controls from Zahedan, southeast of Iran. The maternal levels of IL-23 in circulation were determined via enzyme-linked immunosorbent assay.
Results: The maternal serum levels of IL-23 were increased in PE and its 2 subgroups severe PE and mild PE, so that these increases were significant in PE and severe PE, but not in mild PE compared with the controls (p < 0.001 and p < 0.001, p = 0.08, respectively). Besides, the maternal IL-23 serum level was statically significant in the early onset PE, but not in the late onset-PE group compared to healthy pregnant controls (p < 0.001, p = 0.46 respectively).
Conclusion: The results of our study showed a positive association between IL-23 level and PE, especially in severe type and early onset PE, which suggests that IL-23 may be involved in the pathogenesis of this systemic syndrome.
Objective: To investigate the relationship between the maternal serum level of interleukin (IL)-23, a pro-inflammatory cytokine, PE and its severity risk was investigated.
Materials and Methods: The case-control study included a total of 145 women counting 75 PE cases, 35 healthy pregnant and 35 healthy non-pregnant controls from Zahedan, southeast of Iran. The maternal levels of IL-23 in circulation were determined via enzyme-linked immunosorbent assay.
Results: The maternal serum levels of IL-23 were increased in PE and its 2 subgroups severe PE and mild PE, so that these increases were significant in PE and severe PE, but not in mild PE compared with the controls (p < 0.001 and p < 0.001, p = 0.08, respectively). Besides, the maternal IL-23 serum level was statically significant in the early onset PE, but not in the late onset-PE group compared to healthy pregnant controls (p < 0.001, p = 0.46 respectively).
Conclusion: The results of our study showed a positive association between IL-23 level and PE, especially in severe type and early onset PE, which suggests that IL-23 may be involved in the pathogenesis of this systemic syndrome.
Type of Study: Original Article |
Subject:
Reproductive Biology
References
1. Magee LA, Nicolaides KH, Von Dadelszen P. Preeclampsia. New Engl J Med 2022; 386: 1817-1832. [DOI:10.1056/NEJMra2109523] [PMID]
2. Robillard PY, Dekker G, Scioscia M, Saito S. Progress in the understanding of the pathophysiology of immunologic maladaptation related to early-onset preeclampsia and metabolic syndrome related to late-onset preeclampsia. Am J Obstet Gynecol 2022; 226: S867-S875. [DOI:10.1016/j.ajog.2021.11.019] [PMID]
3. Hurrell A, Duhig K, Vandermolen B, Shennan AH. Recent advances in the diagnosis and management of pre-eclampsia. Fac Rev 2020; 9: 10. [DOI:10.12703/b/9-10] [PMID] [PMCID]
4. Guan C, Zhao F, Yang Z, Tang Q, Wang L, Li X, et al. A review of key cytokines based on gene polymorphism in the pathogenesis of pre‐eclampsia. Am J Reprod Immunol 2022; 87: e13503. [DOI:10.1111/aji.13503] [PMID]
5. Miller D, Motomura K, Galaz J, Gershater M, Lee ED, Romero R, et al. Cellular immune responses in the pathophysiology of preeclampsia. J Leukoc Biol 2022; 111: 237-260. [DOI:10.1002/JLB.5RU1120-787RR] [PMID] [PMCID]
6. Jahantigh D, Mousavi M, Forghani F, Javan MR, Movahedinia S, Rezaei M. Association between maternal circulating IL-27 levels and preeclampsia. Cytokine 2018; 102: 163-167. [DOI:10.1016/j.cyto.2017.08.012] [PMID]
7. Abdo AIK, Tye GJ. Interleukin 23 and autoimmune diseases: Current and possible future therapies. Inflamm Res 2020; 69: 463-480. [DOI:10.1007/s00011-020-01339-9] [PMID]
8. Li H, Tsokos GC. IL-23/IL-17 axis in inflammatory rheumatic diseases. Clin Rev Allergy Immunol 2021; 60: 31-45. [DOI:10.1007/s12016-020-08823-4] [PMID] [PMCID]
9. El Shahaway AA, Abd Elhady RR, Abdelrhman AA, Yahia S. Role of maternal serum interleukin 17 in preeclampsia: Diagnosis and prognosis. J Inflamm Res 2019; 12: 175-180. [DOI:10.2147/JIR.S206800] [PMID] [PMCID]
10. Mohanakrishnan R, Beier S, Deodhar A. IL-23 inhibition for the treatment of psoriatic arthritis. Exp Opin Biol Ther 2022; 22: 59-65. [DOI:10.1080/14712598.2021.1938538] [PMID]
11. Atzeni F, Siragusano C, Masala IF, Antonio C, Valentina P, D'Angelo S. IL-23 in axial spondyloarthritis and psoriatic arthritis: A good fit for biological treatment?. Expert Opin Biol Ther 2022; 22: 843-853. [DOI:10.1080/14712598.2022.2090834] [PMID]
12. Cairns J, Monkley S, Tian S, Angermann B, Liu Z, Öberg L, et al. DOP06 deep characterization of IL-23 pathway in different gut segments and associated plasma biomarkers in inflammatory bowel disease. J Crohn's Colitis 2023; 17 (Suppl.): i64-i67. [DOI:10.1093/ecco-jcc/jjac190.0046]
13. von Essen MR, Søndergaard HB, Petersen ERS, Sellebjerg F. IL-6, IL-12, and IL-23 STAT-pathway genetic risk and responsiveness of lymphocytes in patients with multiple sclerosis. Cells 2019; 8: 285. [DOI:10.3390/cells8030285] [PMID] [PMCID]
14. Rafat Sh, Mohamed YY, Ahmed ME, Abdelaleem EA. Interleukin-23 serum level in systemic lupus erythematosus patients: Relation to disease activity and different disease parameters. Egypt Rheumatol 2022; 44: 139-143. [DOI:10.1016/j.ejr.2021.10.009]
15. Lee KMC, Sherlock JP, Hamilton JA. The role of interleukin (IL)-23 in regulating pain in arthritis. Arthritis Res Ther 2022; 24: 89. [DOI:10.1186/s13075-022-02777-y] [PMID] [PMCID]
16. Sewell GW, Kaser A. Interleukin-23 in the pathogenesis of inflammatory bowel disease and implications for therapeutic intervention. J Crohn's Colitis 2022; 16 (Suppl.): ii3-ii19. [DOI:10.1093/ecco-jcc/jjac034] [PMID] [PMCID]
17. Meng P, Zhao S, Niu X, Fu N, Su S, Wang R, et al. Correction: Ping Meng, et al. Involvement of the interleukin-23/interleukin-17 axis in chronic hepatitis C virus infection and its treatment responses. Int J Mol Sci 2016; 17: 1793.
https://doi.org/10.3390/ijms17111793 [DOI:10.3390/ijms17071070] [PMID] [PMCID]
18. Abbasifard M, Arababadi MK, Bahrehmand F, Bazmandegan Gh, Shahrbabaki ZS, Kamiab Z. Gender affects IL-23 serum levels in the hospitalized COVID-19 infected patients. Am J Clin Exp Immunol 2022; 11: 28-33.
19. Eghbal‐Fard S, Yousefi M, Heydarlou H, Ahmadi M, Taghavi S, Movasaghpour A, et al. The imbalance of Th17/Treg axis involved in the pathogenesis of preeclampsia. J Cell Physiol 2019; 234: 5106-5116. [DOI:10.1002/jcp.27315] [PMID]
20. Jahantigh D, Forghani F, Zidanloo SG. Interleukin-23 receptor (IL-23R) gene polymorphisms and haplotypes associated with the risk of preeclampsia: Evidence from cross-sectional and in silico studies. J Assist Reprod Genet 2019; 36: 1523-1536. [DOI:10.1007/s10815-019-01479-w] [PMID] [PMCID]
21. Mills KHG. IL-17 and IL-17-producing cells in protection versus pathology. Nat Rev Immunol 2023; 23: 38-54. [DOI:10.1038/s41577-022-00746-9] [PMID] [PMCID]
22. Hildenbrand K, Aschenbrenner I, Franke FC, Devergne O, Feige MJ. Biogenesis and engineering of interleukin 12 family cytokines. Trends Biochem Sci 2022; 47: 936-949. [DOI:10.1016/j.tibs.2022.05.005] [PMID]
23. dos Santos Fagundes I, Brendler EP, Nunes Erthal I, Eder Ribeiro RJ, Caron-Lienert RS, Machado DC, et al. Total Th1/Th2 cytokines profile from peripheral blood lymphocytes in normal pregnancy and preeclampsia syndrome. Hypertens Pregnancy 2022; 41: 15-22. [DOI:10.1080/10641955.2021.2008424] [PMID]
24. Braga A, Neves E, Guimarães J, Braga J, Vasconcelos C. Th17/regulatory T cells ratio evolution: A prospective study in a group of healthy pregnant women. J Reprod Immunol 2022; 149: 103468. [DOI:10.1016/j.jri.2021.103468] [PMID]
25. Madadi S, Mohammadinejad S, Alizadegan A, Hojjat-Farsangi M, Dolati S, Samadi Kafil H, et al. Expression level of immune checkpoint inhibitory factors in preeclampsia. Hum Immunol 2022; 83: 628-636. [DOI:10.1016/j.humimm.2022.07.004] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
